Cochrane Abstracts
L‐acetylcarnitine for treating fragile X syndrome
There's more to see -- the rest of this topic is available only to subscribers.
Citation
"L‐acetylcarnitine for Treating Fragile X Syndrome." Cochrane Abstracts, John Wiley & Sons, Inc, 2025. Evidence Central, evidence.unboundmedicine.com/evidence/view/Cochrane/438812/all/L‐acetylcarnitine_for_treating_fragile_X_syndrome.
L‐acetylcarnitine for treating fragile X syndrome. Cochrane Abstracts. John Wiley & Sons, Inc; 2025. https://evidence.unboundmedicine.com/evidence/view/Cochrane/438812/all/L‐acetylcarnitine_for_treating_fragile_X_syndrome. Accessed February 23, 2025.
L‐acetylcarnitine for treating fragile X syndrome. (2025). In Cochrane Abstracts. John Wiley & Sons, Inc. https://evidence.unboundmedicine.com/evidence/view/Cochrane/438812/all/L‐acetylcarnitine_for_treating_fragile_X_syndrome
L‐acetylcarnitine for Treating Fragile X Syndrome [Internet]. In: Cochrane Abstracts. John Wiley & Sons, Inc; 2025. [cited 2025 February 23]. Available from: https://evidence.unboundmedicine.com/evidence/view/Cochrane/438812/all/L‐acetylcarnitine_for_treating_fragile_X_syndrome.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - L‐acetylcarnitine for treating fragile X syndrome
ID - 438812
BT - Cochrane Abstracts
UR - https://evidence.unboundmedicine.com/evidence/view/Cochrane/438812/all/L‐acetylcarnitine_for_treating_fragile_X_syndrome
PB - John Wiley & Sons, Inc
DB - Evidence Central
DP - Unbound Medicine
ER -
